This episode is proudly sponsored by Quartzy.
In this far-reaching conversation, Rahul Chaturvedi speaks with John Lepore, CEO & President of ProFound Therapeutics and CEO-Partner at Flagship Pioneering, tracing a career shaped by a deep commitment to understanding the causal machinery of human disease.
Read MoreThis episode is proudly sponsored by Quartzy.
Biotech is undergoing a scientific redesign, and Jason Kelly reveals to host Alok Tayi how automation, AI-ready datasets, and modular lab technologies are reshaping the future of R&D.
Read MoreIn a conversation rich with strategic insight, Coya Therapeutics CEO Arun Swaminathan unpacks the intersections of scientific innovation, business development discipline, and capital-efficient execution that define today’s most resilient biotechs.
Read MoreNimbus Therapeutics CEO Abbas Kazimi walks Alok Tayi through the company’s evolving pipeline and playbook for choosing the right risks in a noisy biotech environment. Throughout, Abbas returns to a consistent theme: success at Nimbus comes from disciplined target selection, deep collaboration, and a culture that empowers teams to make hard calls in service of patients rather than headlines.
Read MoreJim Tananbaum, Founder & CEO of Foresite Capital, joins Rahul Chaturvedi to dissect the patterns driving biotech innovation, the role of macroeconomic cycles in venture performance, and how disciplined science fuels enduring investment success.
Read MoreHost Rahul Chaturvedi sits down with Geoffrey Duyk, Chief Executive Officer of Grove Biopharma, for a wide-ranging conversation on navigating today’s biotech macro headwinds and building companies that can translate breakthrough science into real patient impact.
Read MoreIn this episode, host Alok Tayi sits down with Michael Metzger, Chief Executive Officer of Syndax, to explore how the company identified breakthrough assets, advanced them through development, and successfully commercialized them within a span of just a few years.
Read MoreWhen biotech meets bold partnerships, new models of innovation emerge. In this episode of the Biotech 2050 Podcast, host Rahul Chaturvedi welcomes Paul Biondi, Managing Partner at Flagship Pioneering, and Uli Stilz, Vice President, R&ED External Innovation Partners at Novo Nordisk, to explore the power of co-creation.
Read MoreIn this episode of Biotech2050, Rahul Chaturvedi speaks with the CEO, Co-Founder & President of Ossium Health about how personal experiences with a reactive healthcare system—and a deep curiosity about the universe—sparked a mission to extend human healthspan through regenerative medicine.
Read MoreCo-CEO & Co-Founder of Guardant Health, AmirAli Talasaz, shares the story behind building one of biotech’s most impactful companies. From a graduate student navigating genomics for the first time to raising over $3 billion and leading a public company, he reflects on lessons learned, obstacles faced, and what it takes to create a patient-first culture at scale.
Read MoreAmy Burroughs, CEO of Terns Pharmaceuticals, joins Alok Tayi to share how she’s leading bold innovation in CML and obesity treatment, driving two high-stakes data readouts in 2025. From a non-linear path through tech, brand management, and Genentech to building resilient biotech teams, Amy reveals why product positioning, tolerability, and mentorship matter just as much as the science.
Read MoreHost Rahul Chaturvedi sits down with Jeremy Bender, CEO of Day One Biopharmaceuticals, to explore the bold mission of transforming pediatric oncology. From earning FDA approval for a groundbreaking brain cancer drug to building a culture rooted in execution and empathy, Jeremy shares lessons from big pharma and startups alike.
Read More
